{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["carrier-free self-assemblies", "enhanced efficiency", "mitochondria-mediated", "natural products", "synergistic antitumor"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": [], "OtherID": [], "GeneralNote": [], "PMID": "38545553", "DateRevised": {"Year": "2024", "Month": "03", "Day": "29"}, "Article": {"Language": ["eng"], "ELocationID": ["1333087", "10.3389/fphar.2024.1333087"], "ArticleDate": [{"Year": "2024", "Month": "03", "Day": "12"}], "Journal": {"ISSN": "1663-9812", "JournalIssue": {"Volume": "15", "PubDate": {"Year": "2024"}}, "Title": "Frontiers in pharmacology", "ISOAbbreviation": "Front Pharmacol"}, "ArticleTitle": "Berberine-based self-assembly agents with enhanced synergistic antitumor efficacy.", "Pagination": {"StartPage": "1333087", "MedlinePgn": "1333087"}, "Abstract": {"AbstractText": ["Tumors are still a major threat to people worldwide. Nanodrug delivery and targeting systems can significantly improve the therapeutic efficacy of chemotherapeutic drugs for antitumor purposes. However, many nanocarriers are likely to exhibit drawbacks such as a complex preparation process, limited drug-loading capacity, untargeted drug release, and toxicity associated with nanocarriers. Therefore, new therapeutic alternatives are urgently needed to develop antitumor drugs. Natural products with abundant scaffold diversity and structural complexity, which are derived from medicinal plants, are important sources of new antitumor drugs. Here, two carrier-free berberine (BBR)-based nanoparticles (NPs) were established to increase the synergistic efficacy of tumor treatment. BBR can interact with glycyrrhetinic acid (GA) and artesunate (ART) to self-assemble BBR-GA and BBR-ART NPs without any nanocarriers, respectively, the formation of which is dominated by electrostatic and hydrophobic interactions. Moreover, BBR-GA NPs could lead to mitochondria-mediated cell apoptosis by regulating mitochondrial fission and dysfunction, while BBR-ART NPs induced ferroptosis in tumor cells. BBR-based NPs have been demonstrated to possess significant tumor targeting and enhanced antitumor properties compared with those of simple monomer mixes both <i>in vitro</i> and <i>in vivo</i>. These carrier-free self-assemblies based on natural products provide a strategy for synergistic drug delivery and thus offer broad prospects for developing enhanced antitumor drugs."], "CopyrightInformation": "Copyright \u00a9 2024 Wang, Li, Zhang, Wu, Zhao, Li, Han and Wang."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China."}], "LastName": "Wang", "ForeName": "Yun", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China."}, {"Identifier": [], "Affiliation": "Department of Rehabilitation, College of Acupuncture and Moxibustion and Massage Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing, China."}], "LastName": "Li", "ForeName": "Zhongrui", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China."}], "LastName": "Zhang", "ForeName": "Haili", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China."}], "LastName": "Wu", "ForeName": "Peiye", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China."}], "LastName": "Zhao", "ForeName": "Yu", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China."}], "LastName": "Li", "ForeName": "Renshi", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Bioactive Natural Product Research, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China."}], "LastName": "Han", "ForeName": "Chao", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Rehabilitation, College of Acupuncture and Moxibustion and Massage Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing, China."}], "LastName": "Wang", "ForeName": "Lei", "Initials": "L"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Pharmacol", "NlmUniqueID": "101548923", "ISSNLinking": "1663-9812"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Astell K. R., Sieger D. (2020). Zebrafish in vivo models of cancer and metastasis. Cold Spring Harb. Perspect. Med. 10, 0370777\u2013a37117. 10.1101/cshperspect.a037077", "ArticleIdList": ["10.1101/cshperspect.a037077", "PMC7397842", "31615862"]}, {"Citation": "Atanasov A. G., Zotchev S. B., Dirsch V. M., Orhan I. E., Banach M., Rollinger J. M., et al. (2021). Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. 20, 200\u2013216. 10.1038/s41573-020-00114-z", "ArticleIdList": ["10.1038/s41573-020-00114-z", "PMC7841765", "33510482"]}, {"Citation": "Bagchi S., Yuan R., Engleman E. G. (2021). Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. Mech. Dis. 16, 223\u2013249. 10.1146/annurev-pathol-042020-042741", "ArticleIdList": ["10.1146/annurev-pathol-042020-042741", "33197221"]}, {"Citation": "Cabral H., Kinoh H., Kataoka K. (2020). Tumor-targeted nanomedicine for immunotherapy. Acc. Chem. Res. 53, 2765\u20132776. 10.1021/acs.accounts.0c00518", "ArticleIdList": ["10.1021/acs.accounts.0c00518", "33161717"]}, {"Citation": "Fu S., Li G., Zang W., Zhou X., Shi K., Zhai Y. (2022). Pure drug nano-assemblies: a facile carrier-free nanoplatform for efficient cancer therapy. Acta Pharm. Sin. B 12, 92\u2013106. 10.1016/j.apsb.2021.08.012", "ArticleIdList": ["10.1016/j.apsb.2021.08.012", "PMC8799886", "35127374"]}, {"Citation": "Hanahan D. (2022). Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346. 10.1158/2159-8290.CD-21-1059", "ArticleIdList": ["10.1158/2159-8290.CD-21-1059", "35022204"]}, {"Citation": "Harrington J. S., Ryter S. W., Plataki M., Price D. R., Choi A. M. K. (2023). Mitochondria in health, disease, and aging. Physiol. Rev. 103 (4), 2349\u20132422. 10.1152/physrev.00058.2021", "ArticleIdList": ["10.1152/physrev.00058.2021", "PMC10393386", "37021870"]}, {"Citation": "Hu Y., Guo N., Yang T., Yan J., Wang W., Li X. (2022). The potential mechanisms by which artemisinin and its derivatives induce ferroptosis in the treatment of cancer. Oxid. Med. Cell. Longev. 2022, 1458143. 10.1155/2022/1458143", "ArticleIdList": ["10.1155/2022/1458143", "PMC8752222", "35028002"]}, {"Citation": "Huang L., Zhao S., Fang F., Xu T., Lan M., Zhang J. (2021). Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy. Biomaterials 268, 120557. 10.1016/j.biomaterials.2020.120557", "ArticleIdList": ["10.1016/j.biomaterials.2020.120557", "33260095"]}, {"Citation": "Islam M. R., Akash S., Rahman M. M., Nowrin F. T., Akter T., Shohag S., et al. (2022). Colon cancer and colorectal cancer: prevention and treatment by potential natural products. Chem. Biol. Interact. 368, 110170. 10.1016/j.cbi.2022.110170", "ArticleIdList": ["10.1016/j.cbi.2022.110170", "36202214"]}, {"Citation": "Kowalska A., Kalinowska-Lis U. (2019). 18\u03b2-Glycyrrhetinic acid: its core biological properties and dermatological applications. Int. J. Cosmet. Sci. 41, 325\u2013331. 10.1111/ics.12548", "ArticleIdList": ["10.1111/ics.12548", "31166601"]}, {"Citation": "Kraus F., Roy K., Pucadyil T. J., Ryan M. T. (2021). Function and regulation of the divisome for mitochondrial fission. Nature 590, 57\u201366. 10.1038/s41586-021-03214-x", "ArticleIdList": ["10.1038/s41586-021-03214-x", "33536648"]}, {"Citation": "Lei G., Zhuang L., Gan B. (2022). Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381\u2013396. 10.1038/s41568-022-00459-0", "ArticleIdList": ["10.1038/s41568-022-00459-0", "PMC10243716", "35338310"]}, {"Citation": "Li H., Wei W., Xu H. (2022). Drug discovery is an eternal challenge for the biomedical sciences. Acta Mat. Medica 1, 1\u20133. 10.15212/amm-2022-1001", "ArticleIdList": ["10.15212/amm-2022-1001"]}, {"Citation": "Li Z., Xu X., Wang Y., Kong L., Han C. (2023). Carrier-free nanoplatforms from natural plants for enhanced bioactivity. J. Adv. Res. 50, 159\u2013176. 10.1016/j.jare.2022.09.013", "ArticleIdList": ["10.1016/j.jare.2022.09.013", "PMC10403678", "36208834"]}, {"Citation": "Liang D., Minikes A. M., Jiang X. (2022). Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol. Cell 82, 2215\u20132227. 10.1016/j.molcel.2022.03.022", "ArticleIdList": ["10.1016/j.molcel.2022.03.022", "PMC9233073", "35390277"]}, {"Citation": "Newman D. J., Cragg G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 83, 770\u2013803. 10.1021/acs.jnatprod.9b01285", "ArticleIdList": ["10.1021/acs.jnatprod.9b01285", "32162523"]}, {"Citation": "Ni K., Luo T., Nash G. T., Lin W. (2020). Nanoscale metal-organic frameworks for cancer immunotherapy. Acc. Chem. Res. 53, 1739\u20131748. 10.1021/acs.accounts.0c00313", "ArticleIdList": ["10.1021/acs.accounts.0c00313", "PMC9359629", "32808760"]}, {"Citation": "Peng X., Songsong T., Tang D., Zhou D., Li Y., Chen Q., et al. (2023). Autonomous metal-organic framework nanorobots for active mitochondria-targeted cancer therapy. Sci. Adv. 9, eadh1736\u201315. 10.1126/sciadv.adh1736", "ArticleIdList": ["10.1126/sciadv.adh1736", "PMC10256165", "37294758"]}, {"Citation": "Rodrigues T., Ferraz L. S. (2020). Therapeutic potential of targeting mitochondrial dynamics in cancer. Biochem. Pharmacol. 182, 114282. 10.1016/j.bcp.2020.114282", "ArticleIdList": ["10.1016/j.bcp.2020.114282", "33058754"]}, {"Citation": "Siegel R. L., Miller K. D., Wagle N. S., Jemal A. (2023). Cancer statistics, 2023. Ca. Cancer J. Clin. 73, 17\u201348. 10.3322/caac.21763", "ArticleIdList": ["10.3322/caac.21763", "36633525"]}, {"Citation": "Song D., Hao J., Fan D. (2020). Biological properties and clinical applications of berberine. Front. Med. 14, 564\u2013582. 10.1007/s11684-019-0724-6", "ArticleIdList": ["10.1007/s11684-019-0724-6", "32335802"]}, {"Citation": "Walensky L. D. (2019). Targeting BAX to drug death directly. Nat. Chem. Biol. 15, 657\u2013665. 10.1038/s41589-019-0306-6", "ArticleIdList": ["10.1038/s41589-019-0306-6", "31209350"]}, {"Citation": "Wang X., Zhang J. B., He K. J., Wang F., Liu C. F. (2021a). Advances of zebrafish in neurodegenerative disease: from models to drug discovery. Front. Pharmacol. 12, 713963\u2013714019. 10.3389/fphar.2021.713963", "ArticleIdList": ["10.3389/fphar.2021.713963", "PMC8317260", "34335276"]}, {"Citation": "Wang Y., Qi H., Liu Y., Duan C., Liu X., Xia T., et al. (2021b). The double-edged roles of ROS in cancer prevention and therapy. Theranostics 11, 4839\u20134857. 10.7150/thno.56747", "ArticleIdList": ["10.7150/thno.56747", "PMC7978298", "33754031"]}, {"Citation": "Wolfram J., Ferrari M. (2019). Clinical cancer nanomedicine. Nano Today 25, 85\u201398. 10.1016/j.nantod.2019.02.005", "ArticleIdList": ["10.1016/j.nantod.2019.02.005", "PMC6662733", "31360214"]}, {"Citation": "Wu J., Sun T., Yang C., Lv T., Bi Y., Xu Y., et al. (2021). Tetrazine-mediated bioorthogonal removal of 3-isocyanopropyl groups enables the controlled release of nitric oxide: in vivo . Biomater. Sci. 9, 1816\u20131825. 10.1039/d0bm01841d", "ArticleIdList": ["10.1039/d0bm01841d", "33458722"]}, {"Citation": "Zhang J., Li Y., Wan J., Zhang M., Li C., Lin J. (2022). Artesunate: a review of its therapeutic insights in respiratory diseases. Phytomedicine 104, 154259. 10.1016/j.phymed.2022.154259", "ArticleIdList": ["10.1016/j.phymed.2022.154259", "35849970"]}, {"Citation": "Zhu S., Yu Q., Huo C., Li Y., He L., Ran B., et al. (2020). Ferroptosis: a novel mechanism of artemisinin and its derivatives in cancer therapy. Curr. Med. Chem. 28, 329\u2013345. 10.2174/0929867327666200121124404", "ArticleIdList": ["10.2174/0929867327666200121124404", "31965935"]}]}], "History": [{"Year": "2023", "Month": "11", "Day": "4"}, {"Year": "2024", "Month": "2", "Day": "27"}, {"Year": "2024", "Month": "3", "Day": "28", "Hour": "6", "Minute": "46"}, {"Year": "2024", "Month": "3", "Day": "28", "Hour": "6", "Minute": "45"}, {"Year": "2024", "Month": "3", "Day": "28", "Hour": "4", "Minute": "13"}, {"Year": "2024", "Month": "3", "Day": "12"}], "PublicationStatus": "epublish", "ArticleIdList": ["38545553", "PMC10967022", "10.3389/fphar.2024.1333087", "1333087"]}}]}